SCHEMBL3552643

SCHEMBL3552643

CCCc1ccc(S(=O)(=O)Nc2ccccc2CCc2ccccc2C(=O)O)cc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.63
ALDH1A1 P00352 2/20 0.57
KDM4E B2RXH2 1/20 0.57
SLC16A3 O15427 5/20 0.56
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
HDAC3 O15379 1/20 0.49
HDAC1 Q13547 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
TSHR P16473 2/20 0.48
MCL1 Q07820 1/20 0.48
CCR1 P32246 1/20 0.47
CCR2 P41597 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3554053 0.95 METAP2 (0.61) METAP2ALDH1A1KDM4ESLC16A3KMT2A
SCHEMBL3558258 0.94 METAP2 (0.60) METAP2ALDH1A1KDM4ESLC16A3KMT2A
SCHEMBL3557729 0.93 METAP2 (0.65) METAP2ALDH1A1KDM4ESLC16A3KMT2A
SCHEMBL3558171 0.92 METAP2 (0.60) METAP2ALDH1A1KDM4ESLC16A3KMT2A
SCHEMBL3554502 0.90 METAP2 (0.64) METAP2ALDH1A1KDM4ESLC16A3KMT2A
SCHEMBL3564276 0.88 SLC16A3 (0.72) METAP2ALDH1A1KDM4ESLC16A3HDAC3
SCHEMBL3555671 0.88 METAP2 (0.57) METAP2ALDH1A1KDM4EKMT2AMEN1
SCHEMBL3556581 0.87 SLC16A3 (0.58) METAP2ALDH1A1KDM4ESLC16A3KMT2A
SCHEMBL3561943 0.86 LMNA (0.58) METAP2ALDH1A1KDM4ESLC16A3TSHR
SCHEMBL3557805 0.86 SLC16A3 (0.65) METAP2ALDH1A1KDM4ESLC16A3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 METAP2 2438/4885ALDH1A1 61/4885KDM4E 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.